NUVB
Nuvation Bio IncNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.57B
P/E Ratio
—
EPS
$-0.60
Beta
1.61
52W High
$9.75
52W Low
$1.57
50-Day MA
$5.06
200-Day MA
$4.70
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $62.90M |
| Gross Profit (TTM) | $53.60M |
| EBITDA | $-211.32M |
| Operating Margin | -81.30% |
| Return on Equity | -53.20% |
| Return on Assets | -23.50% |
| Revenue/Share (TTM) | $0.18 |
| Book Value | $0.88 |
| Price-to-Book | 5.01 |
| Price-to-Sales (TTM) | 25.03 |
| EV/Revenue | 16.87 |
| EV/EBITDA | 2.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 633.00% |
| Shares Outstanding | $346.60M |
| Float | $234.80M |
| % Insiders | 18.79% |
| % Institutions | 62.24% |
Analyst Ratings
Consensus ($12.33 target)
2
Strong Buy7
Buy1
HoldData last updated: 4/9/2026